Dosimetric evaluation of MRI-based treatment planning for prostate cancer

The purpose of this study is to evaluate the dosimetric accuracy of MRI-based treatment planning for prostate cancer using a commercial radiotherapy treatment planning system. Three-dimensional conformal plans for 15 prostate patients were generated using the AcQPlan system. For each patient, dose distributions were calculated using patient CT data with and without heterogeneity correction, and using patient MRI data without heterogeneity correction. MR images were post-processed using the gradient distortion correction (GDC) software. The distortion corrected MR images were fused to the corresponding CT for each patient for target and structure delineation. The femoral heads were delineated based on CT. Other anatomic structures relevant to the treatment (i.e., prostate, seminal vesicles, lymph notes, rectum and bladder) were delineated based on MRI. The external contours were drawn separately on CT and MRI. The same internal contours were used in the dose calculation using CT- and MRI-based geometries by directly transferring them between MRI and CT as needed. Treatment plans were evaluated based on maximum dose, isodose distributions and dose-volume histograms. The results confirm previous investigations that there is no clinically significant dose difference between CT-based prostate plans with and without heterogeneity correction. The difference in the target dose between CT- and MRI-based plans using homogeneous geometry was within 2.5%. Our results suggest that MRI-based treatment planning is suitable for radiotherapy of prostate cancer.     

Investigation of MR image distortion for radiotherapy treatment planning of prostate cancer

MR imaging based treatment planning for radiotherapy of prostate cancer is limited due to MR imaging system related geometrical distortions, especially for patients with large body sizes. On our 0.23 T open scanner equipped with the gradient distortion correction (GDC) software, the residual image distortions after the GDC were <5 mm within the central 36 cm x 36 cm area for a standard 48 cm field of view (FOV). In order to use MR imaging alone for treatment planning the effect of residual MR distortions on external patient contour determination, especially for the peripheral regions outside the 36 cm x 36 cm area, must be investigated and corrected. In this work, we performed phantom measurements to quantify MR system related residual geometric distortions after the GDC and the effective FOV. Our results show that for patients with larger lateral dimensions (>36 cm), the differences in patient external contours between distortion-free CT images and GDC-corrected MR images were 1-2 cm because of the combination of greater gradient distortion and loss of field homogeneity away from the isocentre and the uncertainties in patient setup during CT and MRI scans. The measured distortion maps were used to perform point-by-point corrections for patients with large dimensions inside the effective FOV. Using the point-by-point method, the geometrical distortion after the GDC were reduced to <3 mm for external contour determination and the effective FOV was expanded from 36 cm to 42 cm.     

Optimized bounding boxes for three-dimensional treatment planning in brachytherapy

It is sometimes necessary to determine the optimal value for a direction dependent quantity. Using a search technique based on Powell's quadratic convergent method such an optimal direction can be approximated. The necessary geometric transformations in n-dimensional space are introduced. As an example we consider the approximation of the minimum bounding box of a set of three-dimensional points. Minimum bounding boxes can significantly improve accuracy and efficiency of the calculations in modern brachytherapy treatment planning of the volumes of objects or the dose distribution inside an object. A covariance matrix based approximation method for the minimum bounding box is compared with the results of the search method. The benefits of the use of optimal oriented bounding boxes in brachytherapy treatment planning systems are demonstrated and discussed.     

Dosimetric verification of IMRT treatment planning using Monte Carlo simulations for prostate cancer

The purpose of this work is to investigate the accuracy of dose calculation of a commercial treatment planning system (Corvus, Normos Corp., Sewickley, PA). In this study, 30 prostate intensity-modulated radiotherapy (IMRT) treatment plans from the commercial treatment planning system were recalculated using the Monte Carlo method. Dose-volume histograms and isodose distributions were compared. Other quantities such as minimum dose to the target (D(min)), the dose received by 98% of the target volume (D98), dose at the isocentre (D(iso)), mean target dose (D(mean)) and the maximum critical structure dose (D(max)) were also evaluated based on our clinical criteria. For coplanar plans, the dose differences between Monte Carlo and the commercial treatment planning system with and without heterogeneity correction were not significant. The differences in the isocentre dose between the commercial treatment planning system and Monte Carlo simulations were less than 3% for all coplanar cases. The differences on D98 were less than 2% on average. The differences in the mean dose to the target between the commercial system and Monte Carlo results were within 3%. The differences in the maximum bladder dose were within 3% for most cases. The maximum dose differences for the rectum were less than 4% for all the cases. For non-coplanar plans, the difference in the minimum target dose between the treatment planning system and Monte Carlo calculations was up to 9% if the heterogeneity correction was not applied in Corvus. This was caused by the excessive attenuation of the non-coplanar beams by the femurs. When the heterogeneity correction was applied in Corvus, the differences were reduced significantly. These results suggest that heterogeneity correction should be used in dose calculation for prostate cancer with non-coplanar beam arrangements.     

Incorporating organ movements in IMRT treatment planning for prostate cancer: minimizing uncertainties in the inverse planning process

We investigate an off-line strategy to incorporate inter fraction organ movements in IMRT treatment planning. Nowadays, imaging modalities located in the treatment room allow for several CT scans of a patient during the course of treatment. These multiple CT scans can be used to estimate a probability distribution of possible patient geometries. This probability distribution can subsequently be used to calculate the expectation value of the delivered dose distribution. In order to incorporate organ movements into the treatment planning process, it was suggested that inverse planning could be based on that probability distribution of patient geometries instead of a single snapshot. However, it was shown that a straightforward optimization of the expectation value of the dose may be insufficient since the expected dose distribution is related to several uncertainties: first, this probability distribution has to be estimated from only a few images. And second, the distribution is only sparsely sampled over the treatment course due to a finite number of fractions. In order to obtain a robust treatment plan these uncertainties should be considered and minimized in the inverse planning process. In the current paper, we calculate a 3D variance distribution in addition to the expectation value of the dose distribution which are simultaneously optimized. The variance is used as a surrogate to quantify the associated risks of a treatment plan. The feasibility of this approach is demonstrated for clinical data of prostate patients. Different scenarios of dose expectation values and corresponding variances are discussed.     

6MV与15MVX线在肺癌调强放疗中的剂量学比较

目的：分析、比较用于治疗非小细胞肺癌（NSCLC）的6MV和15MVX线调强放疗（IMRT）计划。方法：随机选择10例NSCLC患者，采用6MV和15MVX射线对每例NSCLC进行IMRT的计划设计，并用ADAC Pinnacle3计划系统提供的卷积／迭加（convolution／superposition）算法对两种能量条件下相同布野方案的IMRT计划进行剂量计算，比较靶区及危及器官的剂量分布、DVH等指标。结果：6MV与15MV放疗计划的等剂量线和DVH相近，6MV计划的靶区剂量均匀性优于15MV计划．而15MV计划高剂量覆盖靶区的程度略优于6MV计划，食管、心脏、脊髓等危及器官的受量基本相同。结论：对于NSCLC，剂量计算应采用能够精确修正组织不均匀性影响的卷积／迭加等算法，调强放疗时应首选6MV X射线。     

Nanoparticle therapeutics for prostate cancer treatment

The application of nanotechnology in medicine is offering many exciting possibilities in healthcare. Engineered nanoparticles have the potential to revolutionize the diagnosis and the therapy of several diseases, particularly by targeted delivery of anticancer drugs and imaging contrast agents. Prostate cancer, the second most common cancer in men, represents one of the major epidemiological problems, especially for patients in the advanced age. There is a substantial interest in developing therapeutic options for treatment of prostate cancer based on use of nanodevices, to overcome the lack of specificity of conventional chemotherapeutic agents as well as for the early detection of precancerous and malignant lesions. Herein, we highlight on the recent development of nanotechnology strategies adopted for the management of prostate cancer. In particular, the combination of targeted and controlled-release polymer nanotechnologies has recently resulted in the clinical development of BIND-014, a promising targeted Docetaxel-loaded nanoprototype, which can be validated for use in the prostate cancer therapy. However, several limitations facing nanoparticle delivery to solid tumours, such as heterogeneity of intratumoural barriers and vasculature, cytotoxicity and/or hypersensitivity reactions to currently available cancer nanomedicines, and the difficult in developing targeted nanoparticles with optimal biophysicochemical properties, should be still addressed for a successful tumour eradication.     

Modelling 6 MV photon beams of a stereotactic radiosurgery system for Monte Carlo treatment planning

The goal of this work is to build a multiple source model to represent the 6 MV photon beams from a Cyberknife stereotactic radiosurgery system for Monte Carlo treatment planning dose calculations. To achieve this goal, the 6 MV photon beams have been characterized and modelled using the EGS4/BEAM Monte Carlo system. A dual source model has been used to reconstruct the particle phase space at a plane immediately above the secondary collimator. The proposed model consists of two circular planar sources for the primary photons and the scattered photons, respectively. The dose contribution of the contaminant electrons was found to be in the order of 10(-3) of the total maximum dose and therefore has been omitted in the source model. Various comparisons have been made to verify the dual source model against the full phase space simulated using the EGS4/BEAM system. The agreement in percent depth dose (PDD) curves and dose profiles between the phase space and the source model was generally within 2%/1 mm for various collimators (5 to 60 mm in diameter) at 80 to 100 cm source-to-surface distances (SSD). Excellent agreement (within 1%/1 mm) was also found between the dose distributions in heterogeneous lung and bone geometry calculated using the original phase space and those calculated using the source model. These results demonstrated the accuracy of the dual source model for Monte Carlo treatment planning dose calculations for the Cyberknife system.     

Commissioning 6 MV photon beams of a stereotactic radiosurgery system for Monte Carlo treatment planning

The goal of this work is to implement a beam commissioning procedure to generate a multiple source model using a set of standard measurement data for possible Monte Carlo treatment planning in the clinic for a Cyberknife stereotactic radiosurgery system. The required measurement data include the central axis depth dose curve (PDD), the dose profile at dmax(= 1.5 cm) of 60 mm cone at 80 cm source-to-surface distance (SSD), and the cone output factors for cones of 5 mm to 60 mm at 80 cm source-to-axis distance (SAD). The employed dual source model has the same structure as the one that has been studied in our previous work while most of the parameters of each source are extracted from the measurement data rather than the beam phase space. The energy spectra will be extracted from the central axis PDD, the fluence distributions will be deconvoluted from the dose profile at dmax, and the source distributions will be determined from the measured cone output factors. Monte Carlo dose calculations in various water phantoms have been performed to verify the beam commissioning procedure. The agreement between the measurements and the commissioning results was within 2%/1 mm for the central axis PDDs and the dose profiles at various depths when an IC-3 chamber was used and within 2% for the cone output factors for various collimator sizes of 5 to 60 mm. Largest difference (9.5%) was observed for the 7.5 mm cone when an IC-10 chamber was used. The large differences can be attributed to the volumetric averaging effect of the IC-10 chamber, whose dimension is comparable to the field of the small cones. The overall agreement between the measurements and the commissioning results is clinically acceptable, which implies that our commissioning tool is adequate for clinical applications of Monte Carlo dose calculations for the Cyberknife stereotactic radiosurgery system.     

Calculation of effective dose from measurements of secondary neutron spectra and scattered photon dose from dynamic MLC IMRT for 6 MV, 15 MV, and 18 MV beam energies

Effective doses were calculated from the delivery of 6 MV, 15 MV, and 18 MV conventional and intensity-modulated radiation therapy (IMRT) prostate treatment plans. ICRP-60 tissue weighting factors were used for the calculations. Photon doses were measured in phantom for all beam energies. Neutron spectra were measured for 15 MV and 18 MV and ICRP-74 quality conversion factors used to calculate ambient dose equivalents. The ambient dose equivalents were corrected for each tissue using neutron depth dose data from the literature. The depth corrected neutron doses were then used as a measure of the neutron component of the ICRP protection quantity, organ equivalent dose. IMRT resulted in an increased photon dose to many organs. However, the IMRT treatments resulted in an overall decrease in effective dose compared to conventional radiotherapy. This decrease correlates to the ability of an intensity-modulated field to minimize dose to critical normal structures in close proximity to the treatment volume. In a comparison of the three beam energies used for the IMRT treatments, 6 MV resulted in the lowest effective dose, while 18 MV resulted in the highest effective dose. This is attributed to the large neutron contribution for 18 MV compared to no neutron contribution for 6 MV.     

Refined gypsum effective attenuation coefficients for Co-60, 6 MV, 10 MV and 18 MV x-rays

We report new effective linear attenuation coefficients (mueff) for refined gypsum for Co-60 and 18 MV x-rays. 6 MV and 10 MV mueff agree with published data. For a 100 cm2 field size (FS), tissue defect x = 1.35 cm, target depth d = 1.65 cm beneath the tissue defect x, mueff is 0.123 cm(-1) (Co-60) and 0.0934 cm(-1) (6 MV). For 100 cm2, x = 1.35 cm, and d = 5.65 cm beneath x, mueff is 0.072 cm(-1) (10 MV), and 0.0614 cm(-1) (18 MV). Ford, mueff decreases about 10% from 25 to 400 cm2. For a given FS, mueff decreases with d by 3%-5% for Co-60, and 3% for 6 MV, 10 MV and 18 MV, but depends on (d - x). For d, when x is large (8 cm), depending on energy and FS, mueff is 2%-4% less than when x is small (2 cm). These data were used in a treatment-planning computer to design compensator filters for a step phantom. Compensation was to within 10% in the compensation plane (CP). Above and below CP, computer-calculated ratios of doses with and without filters were 0.75-1.13. Chamber dose ratios with and without filters were 0.75-1.12.     

Comparison of fixed-beam IMRT, helical tomotherapy, and IMPT for selected cases

A growing number of advanced intensity modulated treatment techniques is becoming available. In this study, the specific strengths and weaknesses of four techniques, static and dynamic multileaf collimator (MLC), conventional linac-based IMRT, helical tomotherapy (HT), and spot-scanning proton therapy (IMPT) are investigated in the framework of biological, EUD-based dose optimization. All techniques were implemented in the same in-house dose optimization tool. Monte Carlo dose computation was used in all cases. All dose-limiting, normal tissue objectives were treated as hard constraints so as to facilitate comparability. Five patient cases were selected to offer each technique a chance to show its strengths: a deep-seated prostate case (for 15 MV linac-based IMRT), a pediatric case (for IMPT), an extensive head-and-neck case (for HT), a lung tumor (for HT), and an optical neurinoma (for noncoplanar linac-based IMRT with a miniMLC). The plans were compared by dose statistics and equivalent uniform dose metrics. All techniques delivered results that were comparable with respect to target coverage and the most dose-limiting normal tissues. Static MLC IMRT struggled to achieve sufficient target coverage at the same level of dose homogeneity in the lung case. IMPT gained the greatest advantage when lung sparing was important, but did not significantly reduce the risk of nearby organs. Tomotherapy and dynamic MLC IMRT showed mostly the same performance. Despite the apparent conceptual differences, all four techniques fare equally well for standard patient cases. The absence of relevant differences is in part due to biological optimization, which offers more freedom to shape the dose than do, e.g., dose volume histogram constraints. Each technique excels for certain classes of highly complex cases, and hence the various modalities should be viewed as complementary, rather than competing.     

6 MV和10 MVX线宫颈癌经典适形照射治疗计划比较分析

目的 研究不同身高、体质量宫颈癌术后患者不同能量6 MV和10 MVX线经典适形四野照射治疗计划的剂量分布,指导临床照射能量的选择.方法 选取21例患者,按体质指数(BMI)分为肥胖组和非肥胖组并进行6 MV和10 MV X线箱式照射治疗的计划设计,统计分析治疗计划相关的剂量学参数.结果 采用10 MV X线的治疗计划:①2组均能降低计划靶区(PTV)的最大剂量(Dmax)、最小剂量(Dmax)、提高适形指数(CI)和不均匀性指数(HI);不能降低平均剂量(Dmax);非肥胖组中位剂量(D50)有变化;肥胖组患者更能有效地降低Dmax和提高HI.②能降低靶区周围危及器官(OAR)的剂量.③更能有效地减少患者中低受量体积.④更能有效地减少机器跳数(MU).结论 对于肥胖宫颈癌患者,采用10 MV X线治疗计划具有优势.